Washington, March 4 – The U.S. International Trade Commission (USITC) has received a complaint alleging that versions of the cancer drug pertuzumab, which are biosimilars, imported into the United States violate U.S. trade law.Several entities of India’s largest biopharmaceutical company...
biocon biologics inc.
biocon biologics international ltd.
biocon biologics ltd.
biocon biologics uk plc
biocon ltd.
biosimilars
breast cancer treatment
genentech
importation
monoclonalantibody
pertuzumab
section 337 tariff act of 1930
trade remedies
united states international trade commission
usitc